Study of the comorbidities in hospitalized patients due to decompensated chronic obstructive pulmonary disease attended in the Internal Medicine Services. ECCO Study;Estudio de las comorbilidades en pacientes hospitalizados por descompensación de la enfermedad pulmonar obstructiva crónica atendidos en los servicios de Medicina Interna. Estudio ECCO

Revista Clinica Espanola

Volumn 210, Issue 3, 2010, Pages 101-108

  Almagro, P ^a   Lopez Garcia F ^b   Cabrera, F J ^c   Montero, L ^d   Morchon D ^e   Diez J ^f   de la Iglesia, F ^g   Roca, F B ^h   Fernandez Ruiz M ⁱ   Castiella, J ^j   Zubillaga, E ^k   Recio, J ^l   Soriano, J B ^m  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

^b HOSPITAL VEGA BAJA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d Especialidad en Oftalmología Hospital Comarcal de la Axarquía Vélez Málaga Málaga   (Spain)

^e HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^f HOSPITAL ROYO VILLANOVA   (Spain)

^g HOSPITAL JUAN CANALEJO   (Spain)

^h HOSPITAL GENERAL DE CASTELLÓN   (Spain)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^j Fundacion Hospital Calahorra   (Spain)

^k HOSPITAL DONOSTIA   (Spain)

^l HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^m Fundacion Caubet CIMERA   (Spain)

more..

Author keywords

Arterial hypertension; Cardiac failure; Chronic obstructive pulmonary disease; Comorbidity; Diabetes mellitus; Hospitalization; Myocardical ischemia

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ALCOHOLISM; ANEMIA; ARTICLE; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONNECTIVE TISSUE DISEASE; CORONARY ARTERY DISEASE; DEMENTIA; DIABETES MELLITUS; EDEMA; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEMIPLEGIA; HEPATITIS; HOSPITAL PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; LEUKEMIA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOPOROSIS; PATIENT SELECTION; PERIPHERAL VASCULAR DISEASE; QUESTIONNAIRE; THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; FEMALE; HOSPITAL DEPARTMENTS; HOSPITALIZATION; HUMANS; INTERNAL MEDICINE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 77749315532     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2009.12.002     Document Type: Article

References (37)

1. World Health Organization. [consultado 29/11/2008]. Disponible en: http://www.who.int/respiratory/copd/burden/en/index.html.
2. Mathers C.D., and Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3 (2006) e442
3. Sobradillo V., Miravitlles M., Gabriel R., Jiménez-Ruiz C., Villasante C., Masa J.F., et al. Geographic variations in prevalence and underdiagnosis of COPD: Results of the IBERPOC multicentre epidemiological study. Chest 118 (2000) 981-989
4. Instituto Nacional de Estadística. Banco de datos Tempus [consultado 29/11/2008]. Disponible en http://www.ine.es/tempus/idb/idbtab.htm.
5. Izquierdo J.L. The burden of COPD in Spain: Results from the confronting COPD survey. Respir Med 97 (2003) 61S-69S
6. Soriano J.B., and Miravitlles M. Datos epidemiológicos de EPOC en España. Arch Bronconeumol 43 (2007) 2-10
7. Sociedad Española de Patología del Aparato Respiratorio (SEPAR) [consultado 2/1/2009]. Disponible en: http://www.separ.es.
8. European Respiratory Society [consultado 2/1/2009]. Disponible en: http://www.ersnet.org.
9. Global strategy for the diagnosis, management and prevention of COPD, Global initiative for chronic obstructive lung disease (GOLD) 2008 [consultado 29/11/2008]. Disponible en: http://www.goldcopd.org.
10. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
11. Bale G., Martínez-Camblor, Burge P.S., and Soriano J.B. Long-term mortality follow-up of the ISOLDE participants: Causes of death during 13 years after trial completion. Respir Med 102 (2008) 1468-1472
12. Sin D.D., Anthonisen N.R., Soriano J.B., and Agustí A.G. Mortality in COPD: Role of comorbidities. Eur Respir J 28 (2006) 1245-1257
13. Chatila W.M., Thomashow B.M., Minai O.A., Criner G.J., and Make B.J. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 5 (2008) 549-555
14. Rodríguez-Roisin, and Soriano J.B. Chronic obstructive pulmonary disease with lung cancer and/or cardiovascular disease. Proc Am Thorac Soc 5 (2008) 842-847
15. Peces-Barba G., Barberà J.A., Agustí A., Casanova C., Casas A., Izquierdo J.L., et al. Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Arch Bronconeumol 5 (2008) 271-281
16. Charlson M.E., Szatrowski T.P., Peterson J., and Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 47 (1994) 1245-1251
17. Almagro P., Calbo E., Ochoa de Echagüen A., Barreiro B., Quintana S., Heredia J.L., et al. Mortality after hospitalization for COPD. Chest 121 (2002) 1441-1448
18. Halpern M.T., Zilberberg M.D., Schmier J.K., Lau E.C., and Shorr A.F. Anemia, costs and mortality in chronic obstructive pulmonary disease. Cost Eff Resour Alloc 4 (2006) 17
19. Ng T.P., Niti M., Tan W.C., Cao Z., Ong K.C., and Eng P. Depressive symptoms and chronic obstructive pulmonary disease: Effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 167 (2007) 60-67
20. Anthonisen N.R., Manfreda J., Warren C.P.W., Hershfield E.S., Harding G.K.M., and Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106 (1987) 196-204
21. Bestall J., Paul E., Garrod R., Garnham R., Jones P., and Wedzicha J. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54 (1999) 581-586
22. García-Aymerich J., Barreiro E., Farrero E., Marrades R.M., Morera J., and Anto J.M. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur Respir J 16 (2000) 1037-1042
23. Zapatero A, Barba R, Grupo de gestión clínica de la SEMI [consultado 29/11/2008]. Disponible en: http://www.fesemi.org/grupos/gestion_clinica/noticias/index.php
24. San Román Terán C., Guijarro Merino R., Gómez Huelgas R., Montero Ribas L., and Grupo de trabajo de EPOC de la Sociedad Española de Medicina Interna. Epidemiología hospitalaria de la EPOC en España. Rev Clin Esp 207 (2007) 3-7
25. Buist A.S., McBurnie M.A., Vollmer W.M., Gillespie S., Burney P., Mannino D.M., et al., BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): A population-based prevalence study. Lancet 370 (2007) 741-750
26. Nishimura K., Izumi T., Tsukino M., and Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 121 (2002) 1434-1440
27. O'Donnell D.E., Aaron S., Bourbeau J., Hernández P., Marciniuk D.D., Balter M., et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2007 update. Can Respir J 14 (2007) 5B-32B
28. Decramer M., Rennard S., Troosters T., Mapel D.W., Giardino N., Mannino D., et al. COPD as a lung disease with systemic consequences-clinical impact, mechanisms, and potential for early intervention. COPD 5 (2008) 235-256
29. Mannino D.M., Thorn D., Swensen A., and Holguin F. Prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in chronic obstructive pulmonary disease. Eur Respir J 32 (2008) 962-969
30. Holguin F., Folch E., Redd S.C., and Mannino D.M. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 128 (2005) 2005-2011
31. Antonelli Incalzi R., Fuso L., De Rosa M., Forastiere F., Rapiti E., Nardecchia B., et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 10 (1997) 2794-2800
32. Render M.L., Weinstein A.S., and Blaustein A.S. Left ventricular dysfunction in deteriorating patients with chronic obstructive pulmonary disease. Chest 107 (1995) 162-168
33. Abroug F., Ouanes-Besbes L., Nciri N., Sellami N., Addad F., Hamda K.B., et al. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: Diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 174 (2006) 990-996
34. Sin D.D., and Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107 (2003) 1514-1519
35. Gray-Donald K., Gibbons L., Shapiro S.H., Macklem P.T., and Martin J.G. Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153 (1996) 961-966
36. Sanjaume M, Almagro P, Rodríguez-Carballeira M, Barreiro B, Heredia JL, Garau J. Mortalidad posthospitalaria en pacientes reingresadores por EPOC. Utilidad del índice BODE. Rev Clin Esp. 2009;209:364-70.
37. Celli B.R., Cote C.G., Marin J.M., Casanova C., Montes de Oca M., Méndez R.A., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350 (2004) 1005-1012